Lakefront Biotherapeutics NV 2018 AR2
The report highlights Galapagos' pivotal year in 2018, marked by the publication of its first Phase 3 results for filgotinib in rheumatoid arthritis. The company expanded its proprietary fibrosis portfolio, initiating Phase 3 trials for GLPG1690 and Phase 2 trials for GLPG1205. Financially, Galapagos ended the year with a strong cash position of ‑1,290.8 million, supported by a successful U.S. public offering. On the sustainability front, the company grew its workforce to 725 employees, representing 38 nationalities, and achieved a 61% female representation overall.
Company: Lakefront Biotherapeutics NV
Sector: Professional & technical services
Country: Belgium
Year: 2018
Type: AR2
Pages: 185
Back to company
Lakefront Biotherapeutics NV
Annual Report
The report highlights Galapagos' pivotal year in 2018, marked by the publication of its first Phase 3 results for filgotinib in rheumatoid arthritis. The company expanded its proprietary fibrosis portfolio, initiating Phase 3 trials for GLPG1690 and Phase 2 trials for GLPG1205. Financially, Galapagos ended the year with a strong cash position of ‑1,290.8 million, supported by a successful U.S. public offering. On the sustainability front, the company grew its workforce to 725 employees, representing 38 nationalities, and achieved a 61% female representation overall.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2018
Reporting Period
Jan 1, 2018 - Dec 31, 2018
Fiscal Year
2018
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women on Board
Women in Management
Workplace Fatalities
Employees